Literature DB >> 21120454

hERG K+ channel-associated cardiac effects of the antidepressant drug desipramine.

Ingo Staudacher1, Lu Wang, Xiaoping Wan, Sabrina Obers, Wolfgang Wenzel, Frank Tristram, Ronald Koschny, Kathrin Staudacher, Jana Kisselbach, Patrick Koelsch, Patrick A Schweizer, Hugo A Katus, Eckhard Ficker, Dierk Thomas.   

Abstract

Cardiac side effects of antidepressant drugs are well recognized. Adverse effects precipitated by the tricyclic drug desipramine include prolonged QT intervals, torsade de pointes tachycardia, heart failure, and sudden cardiac death. QT prolongation has been primarily attributed to acute blockade of hERG/I(Kr) currents. This study was designed to provide a more complete picture of cellular effects associated with desipramine. hERG channels were expressed in Xenopus laevis oocytes and human embryonic kidney (HEK 293) cells, and potassium currents were recorded using patch clamp and two-electrode voltage clamp electrophysiology. Ventricular action potentials were recorded from guinea pig cardiomyocytes. Protein trafficking and cell viability were evaluated in HEK 293 cells and in HL-1 mouse cardiomyocytes by immunocytochemistry, Western blot analysis, or colorimetric MTT assay, respectively. We found that desipramine reduced hERG currents by binding to a receptor site inside the channel pore. hERG protein surface expression was reduced after short-term treatment, revealing a previously unrecognized mechanism. When long-term effects were studied, forward trafficking was impaired and hERG currents were decreased. Action potential duration was prolonged upon acute and chronic desipramine exposure. Finally, desipramine triggered apoptosis in cells expressing hERG channels. Desipramine exerts at least four different cellular effects: (1) direct hERG channel block, (2) acute reduction of hERG surface expression, (3) chronic disruption of hERG trafficking, and (4) induction of apoptosis. These data highlight the complexity of hERG-associated drug effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21120454     DOI: 10.1007/s00210-010-0583-9

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  81 in total

1.  Accuracy of binding mode prediction with a cascadic stochastic tunneling method.

Authors:  Bernhard Fischer; Serena Basili; Holger Merlitz; Wolfgang Wenzel
Journal:  Proteins       Date:  2007-07-01

2.  Flexible side chain models improve enrichment rates in in silico screening.

Authors:  Daria B Kokh; Wolfgang Wenzel
Journal:  J Med Chem       Date:  2008-09-05       Impact factor: 7.446

3.  Identification of IKr and its trafficking disruption induced by probucol in cultured neonatal rat cardiomyocytes.

Authors:  Jun Guo; Hamid Massaeli; Wentao Li; Jianmin Xu; Tao Luo; James Shaw; Lorrie A Kirshenbaum; Shetuan Zhang
Journal:  J Pharmacol Exp Ther       Date:  2007-03-21       Impact factor: 4.030

4.  Cell cycle-dependent expression of HERG1 and HERG1B isoforms in tumor cells.

Authors:  Olivia Crociani; Leonardo Guasti; Manuela Balzi; Andrea Becchetti; Enzo Wanke; Massimo Olivotto; Randy S Wymore; Annarosa Arcangeli
Journal:  J Biol Chem       Date:  2002-11-12       Impact factor: 5.157

5.  Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.

Authors:  S Rajamani; L L Eckhardt; C R Valdivia; C A Klemens; B M Gillman; C L Anderson; K M Holzem; B P Delisle; B D Anson; J C Makielski; C T January
Journal:  Br J Pharmacol       Date:  2006-09-11       Impact factor: 8.739

6.  A structural basis for drug-induced long QT syndrome.

Authors:  J S Mitcheson; J Chen; M Lin; C Culberson; M C Sanguinetti
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-24       Impact factor: 11.205

7.  Protection of neuronal uptake-1 inhibitors in ischemic and anoxic hearts by norepinephrine-dependent and -independent mechanisms.

Authors:  X J Du; E A Woodcock; P J Little; M D Esler; A M Dart
Journal:  J Cardiovasc Pharmacol       Date:  1998-10       Impact factor: 3.105

8.  Desipramine dose prediction based on 24-hour single-dose levels: feasibility and validity.

Authors:  G Bertschy; S Vandel; B Vandel; G Allers; P Bechtel; R Volmat
Journal:  Pharmacopsychiatry       Date:  1989-07       Impact factor: 5.788

Review 9.  hERG potassium channels and cardiac arrhythmia.

Authors:  Michael C Sanguinetti; Martin Tristani-Firouzi
Journal:  Nature       Date:  2006-03-23       Impact factor: 49.962

10.  HERG potassium channels are more frequently expressed in human endometrial cancer as compared to non-cancerous endometrium.

Authors:  A Cherubini; G L Taddei; O Crociani; M Paglierani; A M Buccoliero; L Fontana; I Noci; P Borri; E Borrani; M Giachi; A Becchetti; B Rosati; E Wanke; M Olivotto; A Arcangeli
Journal:  Br J Cancer       Date:  2000-12       Impact factor: 7.640

View more
  18 in total

Review 1.  hERG quality control and the long QT syndrome.

Authors:  Brian Foo; Brittany Williamson; Jason C Young; Gergely Lukacs; Alvin Shrier
Journal:  J Physiol       Date:  2016-02-09       Impact factor: 5.182

2.  The protease inhibitor atazanavir blocks hERG K(+) channels expressed in HEK293 cells and obstructs hERG protein transport to cell membrane.

Authors:  Sheng-na Han; Xiao-yan Sun; Zhao Zhang; Li-rong Zhang
Journal:  Acta Pharmacol Sin       Date:  2015-03-23       Impact factor: 6.150

3.  Antidepressant-induced ubiquitination and degradation of the cardiac potassium channel hERG.

Authors:  Adrienne T Dennis; Drew Nassal; Isabelle Deschenes; Dierk Thomas; Eckhard Ficker
Journal:  J Biol Chem       Date:  2011-08-09       Impact factor: 5.157

4.  Drug-specific risk of severe QT prolongation following acute drug overdose.

Authors:  Sharan L Campleman; Jeffery Brent; Anthony F Pizon; Joshua Shulman; Paul Wax; Alex F Manini
Journal:  Clin Toxicol (Phila)       Date:  2020-04-07       Impact factor: 4.467

5.  Molecular determinants of pentamidine-induced hERG trafficking inhibition.

Authors:  Adrienne T Dennis; Lu Wang; Hanlin Wan; Drew Nassal; Isabelle Deschenes; Eckhard Ficker
Journal:  Mol Pharmacol       Date:  2011-11-01       Impact factor: 4.436

6.  Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid.

Authors:  J Jehle; I Staudacher; F Wiedmann; Pa Schweizer; R Becker; Ha Katus; D Thomas
Journal:  Br J Pharmacol       Date:  2012-12       Impact factor: 8.739

7.  Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.

Authors:  J Jehle; E Ficker; X Wan; I Deschenes; J Kisselbach; F Wiedmann; I Staudacher; C Schmidt; P A Schweizer; R Becker; H A Katus; D Thomas
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

8.  Desipramine prevents cardiac gap junction uncoupling.

Authors:  Joanna Jozwiak; Anna Dietze; Rajiv Grover; Alex Savtschenko; Christian Etz; Friedrich W Mohr; Stefan Dhein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2012-09-11       Impact factor: 3.000

9.  Differential hERG ion channel activity of ultrasmall gold nanoparticles.

Authors:  Annika Leifert; Yu Pan; Anne Kinkeldey; Frank Schiefer; Julia Setzler; Olaf Scheel; Hera Lichtenbeld; Günter Schmid; Wolfgang Wenzel; Willi Jahnen-Dechent; Ulrich Simon
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-29       Impact factor: 11.205

Review 10.  Pharmacological chaperoning: a primer on mechanism and pharmacology.

Authors:  Nancy J Leidenheimer; Katelyn G Ryder
Journal:  Pharmacol Res       Date:  2014-02-14       Impact factor: 7.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.